Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50M | 0 | 0 |
| Gross Profit | -323K | -258K | 50M | -329K | 0 |
| Operating Income | -68M | -51M | -16M | -23M | -29M |
| EBITDA | -68M | -42M | 24M | -24M | -28M |
| Net Income | -60M | -42M | 23M | -24M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$13.51
+5.38% today
1Y Change
+164.92%
Window
Jun 25, 2025 → Jun 17, 2026
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $13.51 and up 164.9% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +0.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +0.5%, free cash flow -66.5% with operating margin 0.0% and ROIC -26.0%. Stock Foundry combines CTNM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CTNM
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CTNM Max Drawdown
-29.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CTNM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$29.0M
-19.6% YoY
Free Cash Flow
-$26.4M
-30.6% YoY
Revenue Growth
+0.0%
EPS Growth
+0.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50M | 0 | 0 |
| Gross Profit | -323K | -258K | 50M | -329K | 0 |
| Operating Income | -68M | -51M | -16M | -23M | -29M |
| EBITDA | -68M | -42M | 24M | -24M | -28M |
| Net Income | -60M | -42M | 23M | -24M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76M | 22M | 16M | 6M | 5M |
| Total Assets | 277M | 213M | 130M | 51M | 71M |
| Total Liabilities | 16M | 15M | 198M | 11M | 9M |
| Shareholder Equity | 261M | 198M | -68M | 39M | 62M |
| Total Debt | 8M | 6M | 193M | 6M | 5M |
| Net Debt | -67M | -16M | 178M | 280K | 279K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
-30.5% YoY
Capital Expenditures
168K
-42.4% YoY
Free Cash Flow
26M
-30.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.1%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.